The latest headlines across every section, pulled from official and open-access sources.
Heat related illness (2:00), graduate medical education funding and primary care (5:40), foreign body ingestion in children (7:40), fall prevention (11:40), chronic constipation (13:20), and oral corticosteroids in children (15:20).
This week, we feature advances in targeted therapy for HER2-mutant lung cancer, interventions to reduce maternal infection, an emerging treatment for hemophilia A, and a new diagnostic test for tuberculosis. We review Barrett’s esophagus and follow a case of systemic illness with kidney failure. Perspectives address GLP-1 drugs and eating disorders, directed blood donation, generic drug safety, and an in-flight medical emergency.
FDA announces results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market.
Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells. — The Harvard Drug Group LLC · Class II · Ongoing
Lack of Assurance of Sterility — Harrow Eye LLC · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. — Leading Pharma, LLC · Class II · Ongoing
Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). It is important to note that this error is limited to the vial itself; the saleable unit of the box of 12 bottles has the correct expiration date printed. — Premier Dental Products Co · Class III · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin — Teva Pharmaceuticals USA, Inc · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots." — Hetero Labs Limited (Unit V) · Class II · Ongoing
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.
Hospital patients at every NHS trust across England can now check their referrals and appointments through the NHS App, making it easier for millions of people to manage their care in one place. Around two-thirds (64%) of all hospital appointments are currently visible through the app, with many patients also able to reschedule or cancel appointments – helping to cut the number of missed […]
The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).
On March 31, NCQA released the HEDIS® MY 2026 Volume 2: Technical Update (Technical Update), which provides comprehensive guidance for organizations reporting HEDIS. With this release, the HEDIS Volume 2: Technical Specifications are “frozen” for MY 2026. Why is the HEDIS Technical Update Important? HEDIS is a set of standardized performance measures that enable consumers, […] The post NCQA Releases HEDIS® MY 2026 Volume 2 Technical Update appeared first on NCQA .
Heart failure (HF) affects more than 64 million individuals worldwide, and 20% to 30% of patients with HF and systolic dysfunction have cardiac dyssynchrony due to conduction system disease. JAMA Review author Mihail Chelu, MD, PhD, of Baylor College of Medicine discusses cardiac resynchronization therapy with JAMA Associate Editor David Simel, MD, MHS. Related Content: Cardiac Resynchronization Therapy Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Daiichi Sankyo
The gap between rising demand for behavioral health services and the healthcare system’s ability to deliver timely, coordinated care continues to widen. Nearly 59 million U.S. adults experience mental illness each year, yet about half do not receive treatment—creating significant downstream consequences for patients, families and the broader healthcare system. As the demand for behavioral […] The post Advancing Behavioral Health Integration in Primary Care: Turning Shared Priorities Into Action appeared first on NCQA .
On April 18, President Trump issued an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, including devastating, complex, and treatment-resistant conditions.
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Merck Sharp Dohme
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.